Ferring’s Noqdirna approved by Scottish Medicines Consortium

Medicines Consortium.

This drug is the only licensed therapy for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults, including the over-65s, and will now be available to Scottish NHS patients at a new low dose tailored to men and women.

In clinical studies, it has been shown to significantly reduce the average number of night-time urinations compared with placebo, while nearly doubling the probability of patients achieving the primary endpoint of the studies.

It was also shown to reduce nocturnal urine volume in men and women by more than 200 ml, as well as increasing the time to first void, allowing people to have an average undisturbed sleep period of approximately 4.5 hours.

A statement from the company said: "The SMC decision is great news for patients and their families, as it now means they will have access to this effective treatment, for a condition that is complex to treat."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.